| __timestamp | Amicus Therapeutics, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 46425000 |
| Thursday, January 1, 2015 | 76943000 | 81491000 |
| Friday, January 1, 2016 | 104793000 | 94291000 |
| Sunday, January 1, 2017 | 149310000 | 121827000 |
| Monday, January 1, 2018 | 270902000 | 160524000 |
| Tuesday, January 1, 2019 | 286378000 | 200000000 |
| Wednesday, January 1, 2020 | 308443000 | 275000000 |
| Friday, January 1, 2021 | 272049000 | 328100000 |
| Saturday, January 1, 2022 | 276677000 | 463800000 |
| Sunday, January 1, 2023 | 152381000 | 565000000 |
| Monday, January 1, 2024 | 731100000 |
Unleashing insights
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Amicus Therapeutics, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.
From 2014 to 2023, Neurocrine Biosciences increased its R&D expenses by over 1,100%, peaking in 2023 with a remarkable 565% increase compared to 2014. Meanwhile, Amicus Therapeutics saw a 220% rise in R&D spending over the same period, with a notable peak in 2020. This trend underscores the growing emphasis on developing groundbreaking therapies.
The data reveals a strategic shift in priorities, with both companies allocating substantial resources to research, aiming to lead the charge in innovative treatments. As the biotech landscape evolves, these investments are crucial for maintaining a competitive edge.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV